SecBot SecBot
PRESS-RELEASE ·Filed May 8, 2026

CGON

CG Oncology Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The BLA completion guidance to Q4 2026 and upcoming PIVOT-006 data in H1 2026 are the key catalysts. The CORE-008 Cohort CX data at AUA on May 16 could provide early read on combination therapy. The $1.1B cash runway through 2029 removes near-term financing risk. Monitor the PIVOT-006 topline for potential approval expansion into intermediate-risk NMIBC.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$69.62
T+0 close · May 8, 2026 · via day close
Latest settled
+2.56%
T+60 · $71.40
Vs SPY
−2.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $69.62entry
  2. T+1 · 6mo ago −0.43%α −0.66% · $69.32
  3. T+5 · 6mo ago −0.12%α −1.59% · $69.54
  4. T+20 · 5mo ago −22.84%α −22.86% · $53.72
  5. T+60 · 3mo ago +2.56%α −2.28% · $71.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, slightly wider than the $0.45 loss a year ago, but the headline is the BLA completion timeline for cretostimogene in BCG-unresponsive NMIBC now guided to Q4 2026, with Phase 3 PIVOT-006 topline data expected in H1 2026. The company raised $391.4M via ATM in Q1, boosting cash to $1.1B, sufficient through 2029, and reported first commercial revenue of $1.07M. The stock will move on the BLA timeline clarity and upcoming PIVOT-006 data readout.

Key Financial Metrics

EPS
−$0.71
est −$0.54 · -31.5%
Revenue
$1.1M
est $453.0K · +139.1% · +1982.7% YoY
Rating
in line

Key Facts

  • BLA completion for cretostimogene in HR BCG-unresponsive NMIBC guided to Q4 2026 (previously no specific timeline)
  • Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC expected H1 2026
  • First results from CORE-008 Cohort CX (cretostimogene + gemcitabine) to be presented at AUA May 16, 2026
  • Net loss of $60.2M ($0.71/share) vs $34.5M ($0.45/share) in Q1 2025
  • Cash, cash equivalents and marketable securities of $1.1B, up from $742.2M at Dec 2025
  • Raised ~$391.4M via ATM facility in Q1 2026 from 6.94M shares
  • First commercial and development revenue of $1.07M reported (vs $0 in Q1 2025)
  • R&D expenses increased to $43.7M from $27.5M; G&A expenses increased to $20.8M from $14.8M

Financial Impact

Net loss widened to $60.2M from $34.5M; cash position strengthened to $1.1B from $742.2M; first commercial revenue of $1.07M reported

net losscash positionrevenueR&D expensesG&A expenses

Risk Factors

  • PIVOT-006 topline data may miss efficacy endpoints, delaying label expansion
  • BLA submission could face CMC delays beyond Q4 2026 guidance
  • Widening net loss trajectory with no near-term profitability expected
  • Competitive landscape in NMIBC (Keytruda, other oncolytic viruses)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3291055

Track record

25 reports on CGON

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026